Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Oxybutazone Tab 100mg	Tablet	100 mg	Oral	Icn Pharmaceuticals	1981-12-31	2005-04-26
Oxyphenbutazone 100mg Tablets	Tablet	100 mg	Oral	Laboratoires Confab Inc	Not applicable	Not applicable

International/Other Brands

Oxyphenbutazone / Reozon

Categories

UNII

A7D84513GV

CAS number

129-20-4

Weight

Average: 324.3737
Monoisotopic: 324.147392516

Chemical Formula

C₁₉H₂₀N₂O₃

InChI Key

HFHZKZSRXITVMK-UHFFFAOYSA-N

InChI

InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3

IUPAC Name

4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione

SMILES

CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1

Pharmacology

Indication

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Target	Actions	Organism
UGroup IIE secretory phospholipase A2	Not Available	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with (4R)-limonene.	Investigational
16-Bromoepiandrosterone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 16-Bromoepiandrosterone.	Investigational
19-norandrostenedione	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione.	Experimental, Illicit
5-androstenedione	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 5-androstenedione.	Experimental, Illicit
Abciximab	Oxyphenbutazone may increase the anticoagulant activities of Abciximab.	Approved
Acebutolol	Oxyphenbutazone may decrease the antihypertensive activities of Acebutolol.	Approved, Investigational
Aceclofenac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aceclofenac.	Approved, Investigational
Acemetacin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Acemetacin.	Approved, Experimental, Investigational
Acenocoumarol	Oxyphenbutazone may increase the anticoagulant activities of Acenocoumarol.	Approved, Investigational
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Acetylsalicylic acid.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Oxyphenbutazone.	Approved
Alclofenac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alclofenac.	Approved, Withdrawn
Alclometasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alclometasone.	Approved
Aldosterone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aldosterone.	Experimental, Investigational
Alendronic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.	Approved
Aliskiren	Oxyphenbutazone may decrease the antihypertensive activities of Aliskiren.	Approved, Investigational
Alminoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alminoprofen.	Experimental
Alprenolol	Oxyphenbutazone may decrease the antihypertensive activities of Alprenolol.	Approved, Withdrawn
Alprostadil	The therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Amcinonide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Amcinonide.	Approved
Amikacin	The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Amikacin.	Approved, Investigational, Vet Approved
Amiloride	Oxyphenbutazone may decrease the antihypertensive activities of Amiloride.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aminosalicylic Acid.	Approved
Amlodipine	The therapeutic efficacy of Amlodipine can be decreased when used in combination with Oxyphenbutazone.	Approved
Ancrod	Oxyphenbutazone may increase the anticoagulant activities of Ancrod.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Andrographolide.	Investigational
Androstenedione	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Androstenedione.	Experimental, Illicit
Anecortave	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anecortave.	Investigational
anecortave acetate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with anecortave acetate.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anisodamine.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Antipyrine.	Approved, Investigational
Antithrombin III human	Oxyphenbutazone may increase the anticoagulant activities of Antithrombin III human.	Approved
Antrafenine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Antrafenine.	Approved
Apixaban	Oxyphenbutazone may increase the anticoagulant activities of Apixaban.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apocynin.	Investigational
Apramycin	Oxyphenbutazone may decrease the excretion rate of Apramycin which could result in a higher serum level.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apremilast.	Approved, Investigational
Arbekacin	Oxyphenbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.	Approved, Investigational
Ardeparin	Oxyphenbutazone may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Argatroban	Oxyphenbutazone may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Arotinolol	Oxyphenbutazone may decrease the antihypertensive activities of Arotinolol.	Investigational
Asenapine	Oxyphenbutazone may decrease the antihypertensive activities of Asenapine.	Approved
Atamestane	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Atamestane.	Investigational
Atenolol	Oxyphenbutazone may decrease the antihypertensive activities of Atenolol.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone.	Approved
Azficel-T	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azficel-T.	Approved, Investigational
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxyphenbutazone.	Approved, Investigational
Azosemide	The therapeutic efficacy of Azosemide can be decreased when used in combination with Oxyphenbutazone.	Investigational
Bacitracin	The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Bacitracin.	Approved, Vet Approved
Balsalazide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Balsalazide.	Approved, Investigational
Becaplermin	Oxyphenbutazone may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Beclomethasone dipropionate	The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Oxyphenbutazone.	Approved, Investigational
Befunolol	Oxyphenbutazone may decrease the antihypertensive activities of Befunolol.	Experimental
Bekanamycin	Oxyphenbutazone may decrease the excretion rate of Bekanamycin which could result in a higher serum level.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benazepril.	Approved, Investigational
Bendazac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bendazac.	Experimental
Bendroflumethiazide	The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone.	Approved
Benorilate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benorilate.	Experimental
Benoxaprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benoxaprofen.	Withdrawn
Benzthiazide	The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Oxyphenbutazone.	Approved
Benzydamine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benzydamine.	Approved
Bepridil	The therapeutic efficacy of Bepridil can be decreased when used in combination with Oxyphenbutazone.	Approved, Withdrawn
Beraprost	The therapeutic efficacy of Beraprost can be decreased when used in combination with Oxyphenbutazone.	Investigational
Betamethasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betamethasone.	Approved, Vet Approved
Betaxolol	Oxyphenbutazone may decrease the antihypertensive activities of Betaxolol.	Approved, Investigational
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Oxyphenbutazone.	Approved, Investigational
Bevantolol	Oxyphenbutazone may decrease the antihypertensive activities of Bevantolol.	Approved
Bevonium	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bevonium.	Experimental
Bimatoprost	The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Bisoprolol	Oxyphenbutazone may decrease the antihypertensive activities of Bisoprolol.	Approved
Bivalirudin	Oxyphenbutazone may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Bopindolol	Oxyphenbutazone may decrease the antihypertensive activities of Bopindolol.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bromfenac.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bucillamine.	Investigational
Bucindolol	Oxyphenbutazone may decrease the antihypertensive activities of Bucindolol.	Investigational
Budesonide	The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Oxyphenbutazone.	Approved
Bufexamac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bufexamac.	Approved, Experimental
Bufuralol	Oxyphenbutazone may decrease the antihypertensive activities of Bufuralol.	Experimental, Investigational
Bumadizone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bumadizone.	Experimental
Bumetanide	The therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxyphenbutazone.	Approved
Bupranolol	Oxyphenbutazone may decrease the antihypertensive activities of Bupranolol.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone.	Experimental
Candesartan cilexetil	The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Oxyphenbutazone.	Approved
Candoxatril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Candoxatril.	Experimental
Capsaicin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Capsaicin.	Approved
Captopril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Captopril.	Approved
Carbaspirin calcium	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Carbaspirin calcium.	Experimental, Investigational
Carboprost Tromethamine	The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.	Approved
Carprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Carprofen.	Approved, Vet Approved, Withdrawn
Carteolol	Oxyphenbutazone may decrease the antihypertensive activities of Carteolol.	Approved
Carvedilol	Oxyphenbutazone may decrease the antihypertensive activities of Carvedilol.	Approved, Investigational
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Oxyphenbutazone.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Celecoxib.	Approved, Investigational
Celiprolol	Oxyphenbutazone may decrease the antihypertensive activities of Celiprolol.	Approved, Investigational
Certoparin	Oxyphenbutazone may increase the anticoagulant activities of Certoparin.	Approved, Investigational
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone.	Approved, Investigational, Vet Approved
Chlorothiazide	The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.	Approved, Vet Approved
Chlorphenesin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Chlorphenesin.	Approved, Vet Approved, Withdrawn
Chlorthalidone	The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxyphenbutazone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Choline magnesium trisalicylate.	Approved
Ciclesonide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ciclesonide.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cilazapril.	Approved
Cimicoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cimicoxib.	Investigational
Cinoxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Ciprofloxacin.	Approved, Investigational
Cisplatin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cisplatin.	Approved
Clobetasol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol.	Approved, Investigational
Clobetasol propionate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol propionate.	Approved
Clobetasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasone.	Approved
Clocortolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clocortolone.	Approved
Clodronic Acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clodronic Acid.	Approved, Investigational, Vet Approved
Clonixin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clonixin.	Approved
Cloprostenol	The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxyphenbutazone.	Vet Approved
Cloranolol	Oxyphenbutazone may decrease the antihypertensive activities of Cloranolol.	Experimental
Colesevelam	Colesevelam can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cortexolone 17α-propionate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cortexolone 17α-propionate.	Investigational
Corticosterone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Corticosterone.	Experimental
Cortisone acetate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cortisone acetate.	Approved, Investigational
Curcumin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Curcumin.	Approved, Investigational
Cyclopenthiazide	The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Oxyphenbutazone.	Experimental
Cyclosporine	The risk or severity of renal failure and hypertension can be increased when Oxyphenbutazone is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabigatran etexilate	Oxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Dalteparin	Oxyphenbutazone may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Oxyphenbutazone may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Oxyphenbutazone may increase the anticoagulant activities of Darexaban.	Investigational
Deferasirox	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deferasirox.	Approved, Investigational
Deflazacort	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deflazacort.	Approved, Investigational
Delapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Delapril.	Investigational
Desipramine	Oxyphenbutazone may decrease the antihypertensive activities of Desipramine.	Approved, Investigational
Desirudin	Oxyphenbutazone may increase the anticoagulant activities of Desirudin.	Approved
Desmopressin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.	Approved
Desonide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desonide.	Approved, Investigational
Desoximetasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoximetasone.	Approved
Desoxycorticosterone acetate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone acetate.	Approved
Desoxycorticosterone Pivalate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone Pivalate.	Experimental, Vet Approved
Dexamethasone	The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Oxyphenbutazone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone isonicotinate.	Vet Approved
Dexibuprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexibuprofen.	Approved, Investigational
Dexketoprofen	The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxyphenbutazone.	Approved, Investigational
Dexniguldipine	The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Oxyphenbutazone.	Experimental
Dextran	Oxyphenbutazone may increase the anticoagulant activities of Dextran.	Approved, Investigational, Vet Approved
Dibekacin	Oxyphenbutazone may decrease the excretion rate of Dibekacin which could result in a higher serum level.	Experimental
Dibotermin alfa	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dibotermin alfa.	Approved, Investigational
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Oxyphenbutazone.	Approved, Vet Approved
Dicoumarol	Oxyphenbutazone may increase the anticoagulant activities of Dicoumarol.	Approved
Difenpiramide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difenpiramide.	Experimental
Diflorasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Diflorasone.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Diflunisal.	Approved, Investigational
Difluocortolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluocortolone.	Approved, Investigational, Withdrawn
Difluprednate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluprednate.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Oxyphenbutazone.	Approved
Dihydrostreptomycin	Oxyphenbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.	Investigational, Vet Approved
Diltiazem	The therapeutic efficacy of Diltiazem can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Dinoprost	The therapeutic efficacy of Dinoprost can be decreased when used in combination with Oxyphenbutazone.	Investigational
Dinoprost Tromethamine	The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.	Approved, Vet Approved
Dinoprostone	The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxyphenbutazone.	Approved
Doxazosin	The therapeutic efficacy of Doxazosin can be decreased when used in combination with Oxyphenbutazone.	Approved
Drospirenone	Oxyphenbutazone may increase the hyperkalemic activities of Drospirenone.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Droxicam.	Withdrawn
Duvelisib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Duvelisib.	Investigational
E-6201	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with E-6201.	Investigational
Edetic Acid	Oxyphenbutazone may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Oxyphenbutazone may increase the anticoagulant activities of Edoxaban.	Approved
Efonidipine	The therapeutic efficacy of Efonidipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Enalapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Enalaprilat.	Approved
Enoxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Enoxacin.	Approved, Investigational
Enoxaparin	Oxyphenbutazone may increase the anticoagulant activities of Enoxaparin.	Approved
Enprostil	The therapeutic efficacy of Enprostil can be decreased when used in combination with Oxyphenbutazone.	Experimental
Epanolol	Oxyphenbutazone may decrease the antihypertensive activities of Epanolol.	Experimental
Epirizole	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Epirizole.	Approved
Epitizide	The therapeutic efficacy of Epitizide can be decreased when used in combination with Oxyphenbutazone.	Experimental
Eplerenone	Oxyphenbutazone may decrease the antihypertensive activities of Eplerenone.	Approved
Epoprostenol	The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone.	Approved
Equilenin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilenin.	Experimental
Equilin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilin.	Approved
Esatenolol	Oxyphenbutazone may decrease the antihypertensive activities of Esatenolol.	Experimental
Esmolol	Oxyphenbutazone may decrease the antihypertensive activities of Esmolol.	Approved
Estrone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone.	Approved
Estrone sulfate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone sulfate.	Approved
Etacrynic acid	The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etanercept.	Approved, Investigational
Ethenzamide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ethenzamide.	Experimental
Ethyl biscoumacetate	Oxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etidronic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etidronic acid.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etodolac.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etofenamate.	Approved, Investigational
Etoricoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etoricoxib.	Approved, Investigational
Evening primrose oil	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Evening primrose oil.	Investigational, Nutraceutical
Exisulind	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Exisulind.	Investigational
Felbinac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Felbinac.	Experimental
Felodipine	The therapeutic efficacy of Felodipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenbufen.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenoprofen.	Approved
Fenprostalene	The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Oxyphenbutazone.	Vet Approved
Fentiazac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fentiazac.	Experimental
Feprazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Feprazone.	Experimental
Ferulic acid	Oxyphenbutazone may increase the anticoagulant activities of Ferulic acid.	Experimental
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Oxyphenbutazone.	Approved, Investigational
Fleroxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Oxyphenbutazone.	Approved, Withdrawn
Fluasterone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluasterone.	Investigational
Fludrocortisone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fludrocortisone.	Approved, Investigational
Fluindione	Oxyphenbutazone may increase the anticoagulant activities of Fluindione.	Approved, Investigational
Flumequine	Oxyphenbutazone may increase the neuroexcitatory activities of Flumequine.	Withdrawn
Flumethasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flumethasone.	Approved, Vet Approved
Flunisolide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunisolide.	Approved, Investigational
Flunixin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunixin.	Vet Approved
Flunoxaprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunoxaprofen.	Experimental
Fluocinolone Acetonide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinolone Acetonide.	Approved, Investigational, Vet Approved
Fluocinonide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinonide.	Approved, Investigational
Fluocortolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocortolone.	Approved, Withdrawn
Fluorometholone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluorometholone.	Approved, Investigational
Fluprednidene	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluprednidene.	Approved, Withdrawn
Fluprednisolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluprednisolone.	Approved
Fluprostenol	The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Oxyphenbutazone.	Vet Approved
Flurandrenolide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flurandrenolide.	Approved
Flurbiprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flurbiprofen.	Approved, Investigational
Fluticasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone.	Approved, Experimental, Investigational
Fluticasone furoate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone furoate.	Approved
Fluticasone propionate	The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Oxyphenbutazone.	Approved
Folic Acid	The therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxyphenbutazone.	Approved, Nutraceutical, Vet Approved
Fondaparinux	Oxyphenbutazone may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Forasartan	The risk or severity of adverse effects can be increased when Forasartan is combined with Oxyphenbutazone.	Experimental
Formestane	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Formestane.	Approved, Investigational, Withdrawn
Fosinopril	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Fosinopril.	Approved
Framycetin	Oxyphenbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.	Approved
Furosemide	The therapeutic efficacy of Furosemide can be decreased when used in combination with Oxyphenbutazone.	Approved, Vet Approved
Gabexate	Oxyphenbutazone may increase the anticoagulant activities of Gabexate.	Investigational
Garenoxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Garenoxacin.	Investigational
Gatifloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin.	Approved, Investigational
Gemeprost	The therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxyphenbutazone.	Approved, Withdrawn
Gemifloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Gemifloxacin.	Approved, Investigational
Geneticin	Oxyphenbutazone may decrease the excretion rate of Geneticin which could result in a higher serum level.	Experimental
Gentamicin	Oxyphenbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.	Approved, Vet Approved
GENTAMICIN C1A	Oxyphenbutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.	Experimental
Ginseng	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ginseng.	Approved, Investigational, Nutraceutical
Glipizide	The protein binding of Glipizide can be decreased when combined with Oxyphenbutazone.	Approved, Investigational
Glyburide	The protein binding of Glyburide can be decreased when combined with Oxyphenbutazone.	Approved
Grepafloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Guacetisal.	Experimental
Guanfacine	The therapeutic efficacy of Guanfacine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Halcinonide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Halcinonide.	Approved, Investigational, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.	Approved
HE3286	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HE3286.	Investigational
Heparin	Oxyphenbutazone may increase the anticoagulant activities of Heparin.	Approved, Investigational
Higenamine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Higenamine.	Investigational
Hydralazine	Oxyphenbutazone may decrease the antihypertensive activities of Hydralazine.	Approved
Hydrochlorothiazide	The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone.	Approved, Vet Approved
Hydrocortisone	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Oxyphenbutazone.	Approved, Vet Approved
Hydrocortisone acetate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Oxyphenbutazone.	Approved, Vet Approved
Hydrocortisone butyrate	The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Oxyphenbutazone.	Approved, Vet Approved
Hydroflumethiazide	The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Hygromycin B	Oxyphenbutazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.	Vet Approved
Ibandronate	The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Ibandronate.	Approved, Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibuproxam.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icatibant.	Approved, Investigational
Icosapent	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icosapent.	Approved, Nutraceutical
Idraparinux	Oxyphenbutazone may increase the anticoagulant activities of Idraparinux.	Investigational
Iloprost	The therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Imidapril.	Investigational
Imidazole salicylate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Imidazole salicylate.	Experimental
Indapamide	The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.	Approved
Indenolol	Oxyphenbutazone may decrease the antihypertensive activities of Indenolol.	Withdrawn
Indobufen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indobufen.	Investigational
Indomethacin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indomethacin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indoprofen.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.	Approved, Investigational
Isepamicin	Oxyphenbutazone may decrease the excretion rate of Isepamicin which could result in a higher serum level.	Experimental
Isoxicam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Isoxicam.	Withdrawn
Isradipine	The therapeutic efficacy of Isradipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Istaroxime	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Istaroxime.	Investigational
Kanamycin	Oxyphenbutazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.	Approved, Investigational, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Kebuzone.	Experimental
Ketoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ketoprofen.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Oxyphenbutazone.	Approved
Labetalol	Oxyphenbutazone may decrease the antihypertensive activities of Labetalol.	Approved
Lacidipine	The therapeutic efficacy of Lacidipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Landiolol	Oxyphenbutazone may decrease the antihypertensive activities of Landiolol.	Investigational
Latanoprost	The therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Latanoprostene Bunod	The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Oxyphenbutazone.	Approved, Investigational
Lepirudin	Oxyphenbutazone may increase the anticoagulant activities of Lepirudin.	Approved
Lercanidipine	The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Letaxaban	Oxyphenbutazone may increase the anticoagulant activities of Letaxaban.	Investigational
Levobetaxolol	Oxyphenbutazone may decrease the antihypertensive activities of Levobetaxolol.	Approved, Investigational
Levobunolol	Oxyphenbutazone may decrease the antihypertensive activities of Levobunolol.	Approved
Levofloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.	Approved, Investigational
Limaprost	The therapeutic efficacy of Limaprost can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisinopril.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisofylline.	Investigational
Lithium cation	The serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.	Experimental
Lomefloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Lomefloxacin.	Approved, Investigational
Lonazolac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lonazolac.	Experimental
Lornoxicam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.	Approved, Investigational
Losartan	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Oxyphenbutazone.	Approved
Loteprednol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loteprednol.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loxoprofen.	Approved, Investigational
Lubiprostone	The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Lumiracoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lumiracoxib.	Approved, Investigational
Luprostiol	The therapeutic efficacy of Luprostiol can be decreased when used in combination with Oxyphenbutazone.	Vet Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Magnesium salicylate.	Approved
Manidipine	The therapeutic efficacy of Manidipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Oxyphenbutazone.	Approved, Investigational
ME-609	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with ME-609.	Investigational
Meclofenamic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Meclofenamic acid.	Approved, Vet Approved
Medrogestone	The serum concentration of Medrogestone can be decreased when it is combined with Oxyphenbutazone.	Approved
Medrysone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Medrysone.	Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mefenamic acid.	Approved
Melagatran	Oxyphenbutazone may increase the anticoagulant activities of Melagatran.	Experimental
Melengestrol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Melengestrol.	Vet Approved
Meloxicam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Meloxicam.	Approved, Vet Approved
Mepindolol	Oxyphenbutazone may decrease the antihypertensive activities of Mepindolol.	Experimental
Mesalazine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mesalazine.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole.	Approved, Investigational, Withdrawn
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone.	Approved
Methyclothiazide	The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.	Approved
Methylprednisolone	The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Oxyphenbutazone.	Approved, Vet Approved
Metipranolol	Oxyphenbutazone may decrease the antihypertensive activities of Metipranolol.	Approved
Metolazone	The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.	Approved
Metoprolol	Oxyphenbutazone may decrease the antihypertensive activities of Metoprolol.	Approved, Investigational
Mibefradil	The therapeutic efficacy of Mibefradil can be decreased when used in combination with Oxyphenbutazone.	Investigational, Withdrawn
Micronomicin	Oxyphenbutazone may decrease the excretion rate of Micronomicin which could result in a higher serum level.	Experimental
Mifamurtide	The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Oxyphenbutazone.	Approved, Experimental
Minoxidil	The therapeutic efficacy of Minoxidil can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Misoprostol	The therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxyphenbutazone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mizoribine.	Investigational
Moexipril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Moexipril.	Approved
Mofebutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mofebutazone.	Experimental
Mometasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone.	Approved, Vet Approved
Morniflumate	The risk or severity of adverse effects can be increased when Morniflumate is combined with Oxyphenbutazone.	Approved
Moxifloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nabumetone.	Approved
Nadolol	Oxyphenbutazone may decrease the antihypertensive activities of Nadolol.	Approved
Nadroparin	Oxyphenbutazone may increase the anticoagulant activities of Nadroparin.	Approved, Investigational
Nafamostat	Oxyphenbutazone may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Oxyphenbutazone.	Approved
Naftopidil	The therapeutic efficacy of Naftopidil can be decreased when used in combination with Oxyphenbutazone.	Investigational
Nalidixic Acid	Oxyphenbutazone may increase the neuroexcitatory activities of Nalidixic Acid.	Approved, Investigational
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Oxyphenbutazone.	Approved, Vet Approved
NCX 1022	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with NCX 1022.	Investigational
Neamine	Oxyphenbutazone may decrease the excretion rate of Neamine which could result in a higher serum level.	Experimental
Nebivolol	Oxyphenbutazone may decrease the antihypertensive activities of Nebivolol.	Approved, Investigational
Nemonoxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Nemonoxacin.	Investigational
Neomycin	The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Neomycin.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nepafenac.	Approved, Investigational
Netilmicin	Oxyphenbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.	Approved, Investigational
Nicardipine	The therapeutic efficacy of Nicardipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Nifenazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nifenazone.	Experimental
Niflumic Acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid.	Approved
Niguldipine	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Oxyphenbutazone.	Experimental
Nilvadipine	The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Nimesulide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.	Approved, Investigational, Withdrawn
Nimodipine	The therapeutic efficacy of Nimodipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Nisoldipine	The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Oxyphenbutazone.	Approved
Nitrendipine	The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Nitroaspirin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nitroaspirin.	Investigational
Norfloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Norfloxacin.	Approved
Ofloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Ofloxacin.	Approved
Oleoyl-estrone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oleoyl-estrone.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.	Approved
Olsalazine	Oxyphenbutazone may increase the nephrotoxic activities of Olsalazine.	Approved
Omacetaxine mepesuccinate	The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Omacetaxine mepesuccinate.	Approved, Investigational
Omapatrilat	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Omapatrilat.	Investigational
Orgotein	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Orgotein.	Vet Approved
Otamixaban	Oxyphenbutazone may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oxaprozin.	Approved
Oxolinic acid	Oxyphenbutazone may increase the neuroexcitatory activities of Oxolinic acid.	Experimental
Oxprenolol	Oxyphenbutazone may decrease the antihypertensive activities of Oxprenolol.	Approved
Palmidrol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Palmidrol.	Experimental, Nutraceutical
Pamidronate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pamidronate.	Approved
Paramethasone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Paramethasone.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parecoxib.	Approved
Paromomycin	The risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Paromomycin.	Approved, Investigational
Parthenolide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parthenolide.	Approved, Investigational
Pazufloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Pazufloxacin.	Investigational
Pefloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Pefloxacin.	Approved
Penbutolol	Oxyphenbutazone may decrease the antihypertensive activities of Penbutolol.	Approved, Investigational
Pentaerythritol Tetranitrate	Oxyphenbutazone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.	Approved
Pentosan Polysulfate	Oxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Perindopril.	Approved
Phenindione	Oxyphenbutazone may increase the anticoagulant activities of Phenindione.	Approved, Investigational
Phenprocoumon	Oxyphenbutazone may increase the anticoagulant activities of Phenprocoumon.	Approved, Investigational
Phenylbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Phenylbutazone.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone.	Approved, Investigational
Pindolol	Oxyphenbutazone may decrease the antihypertensive activities of Pindolol.	Approved, Investigational
Pipemidic acid	Oxyphenbutazone may increase the neuroexcitatory activities of Pipemidic acid.	Experimental
Piretanide	The therapeutic efficacy of Piretanide can be decreased when used in combination with Oxyphenbutazone.	Approved
Pirfenidone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone.	Approved, Investigational
Piromidic acid	Oxyphenbutazone may increase the neuroexcitatory activities of Piromidic acid.	Experimental
Piroxicam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Piroxicam.	Approved, Investigational
Pirprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirprofen.	Experimental
Pitolisant	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pitolisant.	Approved, Investigational
Platelet Activating Factor	Oxyphenbutazone may decrease the antihypertensive activities of Platelet Activating Factor.	Experimental
Plazomicin	Oxyphenbutazone may decrease the excretion rate of Plazomicin which could result in a higher serum level.	Approved, Investigational
Polythiazide	The therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxyphenbutazone.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pomalidomide.	Approved
Potassium Citrate	Oxyphenbutazone may increase the anticoagulant activities of Potassium Citrate.	Approved, Investigational, Vet Approved
Practolol	Oxyphenbutazone may decrease the antihypertensive activities of Practolol.	Approved
Pralatrexate	The serum concentration of Pralatrexate can be increased when it is combined with Oxyphenbutazone.	Approved, Investigational
Pranoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pranoprofen.	Experimental, Investigational
Prasterone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prasterone.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prasterone sulfate.	Investigational
Prednicarbate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednicarbate.	Approved, Investigational
Prednisolone	The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Oxyphenbutazone.	Approved, Vet Approved
Prednisone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pregnenolone.	Approved, Experimental, Investigational
Probenecid	The serum concentration of Oxyphenbutazone can be increased when it is combined with Probenecid.	Approved, Investigational
Proglumetacin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Proglumetacin.	Experimental
Propacetamol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Propacetamol.	Approved, Investigational
Propafenone	Oxyphenbutazone may decrease the antihypertensive activities of Propafenone.	Approved
Propranolol	Oxyphenbutazone may decrease the antihypertensive activities of Propranolol.	Approved, Investigational
Propyphenazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Propyphenazone.	Experimental
Proquazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Proquazone.	Experimental
Prostaglandin B2	The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Oxyphenbutazone.	Experimental
Prostaglandin G2	The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Oxyphenbutazone.	Experimental
Prostalene	The therapeutic efficacy of Prostalene can be decreased when used in combination with Oxyphenbutazone.	Vet Approved
Protein C	Oxyphenbutazone may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Oxyphenbutazone may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Oxyphenbutazone may increase the anticoagulant activities of Protocatechualdehyde.	Approved
Prulifloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with PTC299.	Investigational
Puromycin	Oxyphenbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.	Experimental
Quinapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Quinapril.	Approved, Investigational
Quinethazone	The therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxyphenbutazone.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ramipril.	Approved
Rescinnamine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rescinnamine.	Approved
Resveratrol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Resveratrol.	Approved, Experimental, Investigational
Reviparin	Oxyphenbutazone may increase the anticoagulant activities of Reviparin.	Approved, Investigational
Ribostamycin	Oxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.	Approved, Investigational
Rimexolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rimexolone.	Approved
Risedronate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate.	Approved, Investigational
Rivaroxaban	Oxyphenbutazone may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rofecoxib.	Approved, Investigational, Withdrawn
Rosoxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin.	Approved, Investigational
Rufloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Rufloxacin.	Experimental
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Oxyphenbutazone.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxyphenbutazone.	Approved, Investigational, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salsalate.	Approved
Saprisartan	The risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone.	Experimental
Saralasin	The risk or severity of adverse effects can be increased when Saralasin is combined with Oxyphenbutazone.	Investigational
Sarilumab	Sarilumab may increase the immunosuppressive activities of Oxyphenbutazone.	Approved, Investigational
Seliciclib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seliciclib.	Investigational
Semapimod	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Semapimod.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seratrodast.	Approved
Serrapeptase	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Serrapeptase.	Investigational
Sisomicin	Oxyphenbutazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.	Investigational
Sitafloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Sitafloxacin.	Experimental, Investigational
Sodium Citrate	The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Sodium Citrate.	Approved, Investigational
Sodium phosphate, monobasic	The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Oxyphenbutazone.	Approved
Sotalol	Oxyphenbutazone may decrease the antihypertensive activities of Sotalol.	Approved
Sparfloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Sparfloxacin.	Approved, Investigational
Spirapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Spirapril.	Approved
Spironolactone	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Spironolactone.	Approved
SRT501	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with SRT501.	Investigational
Streptomycin	Oxyphenbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.	Approved, Vet Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxyphenbutazone.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Oxyphenbutazone.	Approved, Investigational
Sulodexide	Oxyphenbutazone may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sulprostone	The therapeutic efficacy of Sulprostone can be decreased when used in combination with Oxyphenbutazone.	Investigational
Suprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Suprofen.	Approved, Withdrawn
Suxibuzone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Suxibuzone.	Experimental
Tacrolimus	Oxyphenbutazone may increase the nephrotoxic activities of Tacrolimus.	Approved, Investigational
Tafluprost	The therapeutic efficacy of Tafluprost can be decreased when used in combination with Oxyphenbutazone.	Approved
Talinolol	Oxyphenbutazone may decrease the antihypertensive activities of Talinolol.	Investigational
Talniflumate	The risk or severity of adverse effects can be increased when Talniflumate is combined with Oxyphenbutazone.	Approved
Tarenflurbil	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tarenflurbil.	Investigational
Tasosartan	The risk or severity of adverse effects can be increased when Tasosartan is combined with Oxyphenbutazone.	Approved
Technetium Tc-99m etidronate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium Tc-99m etidronate.	Approved
Technetium Tc-99m medronate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium Tc-99m medronate.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone.	Approved, Investigational
Temafloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Temafloxacin.	Withdrawn
Temocapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Temocapril.	Experimental, Investigational
Tenidap	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tenidap.	Experimental
Tenofovir disoproxil	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tenofovir disoproxil.	Approved, Investigational
Tenoxicam	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tenoxicam.	Approved
Tepoxalin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tepoxalin.	Vet Approved
Terbutaline	Oxyphenbutazone may decrease the antihypertensive activities of Terbutaline.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide.	Approved
Tertatolol	Oxyphenbutazone may decrease the antihypertensive activities of Tertatolol.	Experimental
Testosterone cypionate	The serum concentration of Oxyphenbutazone can be increased when it is combined with Testosterone cypionate.	Approved
Testosterone enanthate	The serum concentration of Oxyphenbutazone can be increased when it is combined with Testosterone enanthate.	Approved
Tetrahydropalmatine	The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Oxyphenbutazone.	Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tiaprofenic acid.	Approved
Tiludronic acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tiludronic acid.	Approved, Investigational, Vet Approved
Timolol	Oxyphenbutazone may decrease the antihypertensive activities of Timolol.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tinoridine.	Investigational
Tixocortol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tixocortol.	Approved, Withdrawn
Tobramycin	Oxyphenbutazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid.	Approved, Investigational
Tolmetin	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolmetin.	Approved
Torasemide	The therapeutic efficacy of Torasemide can be decreased when used in combination with Oxyphenbutazone.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Trandolapril.	Approved
Travoprost	The therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone.	Approved
Treprostinil	The risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone.	Approved, Investigational
Triamcinolone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triamcinolone.	Approved, Vet Approved
Triamterene	Oxyphenbutazone may decrease the antihypertensive activities of Triamterene.	Approved
Tribenoside	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tribenoside.	Experimental
Trichlormethiazide	The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxyphenbutazone.	Approved, Vet Approved
Triptolide	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triptolide.	Investigational
Trolamine salicylate	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Trolamine salicylate.	Approved
Trovafloxacin	Oxyphenbutazone may increase the neuroexcitatory activities of Trovafloxacin.	Approved, Investigational, Withdrawn
Troxerutin	Oxyphenbutazone may increase the anticoagulant activities of Troxerutin.	Investigational
Ulobetasol	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ulobetasol.	Approved
Unoprostone	The therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxyphenbutazone.	Approved, Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Valdecoxib.	Approved, Investigational, Withdrawn
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone.	Approved, Investigational
Vancomycin	Oxyphenbutazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.	Approved
Warfarin	Oxyphenbutazone may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Oxyphenbutazone may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen.	Approved, Investigational
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Oxyphenbutazone.	Approved, Investigational, Withdrawn
Zofenopril	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zofenopril.	Experimental
Zoledronic acid	The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Zoledronic acid.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac.	Withdrawn

Food Interactions

Take with food to reduce irritation.

References

General References

Not Available

External Links

KEGG Compound: C19494
PubChem Compound: 4641
PubChem Substance: 46507285
ChemSpider: 4480
BindingDB: 200298
ChEBI: 76258
ChEMBL: CHEMBL1228
PharmGKB: PA450750
HET: OPB
Wikipedia: Oxyphenbutazone

ATC Codes

S01BC02 — Oxyphenbutazone

M01AA03 — Oxyphenbutazone

M02AA04 — Oxyphenbutazone

AHFS Codes

28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents

Clinical Trials

Clinical Trials: Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Tablet	Oral	100 mg

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	96 °C	PhysProp
water solubility	60 mg/L (at 30 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	2.72	HANSCH,C ET AL. (1995)
logS	-3.73	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.256 mg/mL	ALOGPS
logP	2.79	ALOGPS
logP	3.83	ChemAxon
logS	-3.1	ALOGPS
pKa (Strongest Acidic)	4.87	ChemAxon
pKa (Strongest Basic)	-6	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	60.85 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	90.74 m³·mol^-1	ChemAxon
Polarizability	35.14 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9238
Caco-2 permeable	+	0.5303
P-glycoprotein substrate	Non-substrate	0.7216
P-glycoprotein inhibitor I	Non-inhibitor	0.7803
P-glycoprotein inhibitor II	Inhibitor	0.6587
Renal organic cation transporter	Non-inhibitor	0.8981
CYP450 2C9 substrate	Non-substrate	0.6167
CYP450 2D6 substrate	Non-substrate	0.8844
CYP450 3A4 substrate	Non-substrate	0.5538
CYP450 1A2 substrate	Inhibitor	0.7253
CYP450 2C9 inhibitor	Inhibitor	0.5
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.9035
CYP450 3A4 inhibitor	Inhibitor	0.796
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6021
Ames test	AMES toxic	0.9107
Carcinogenicity	Non-carcinogens	0.7686
Biodegradation	Not ready biodegradable	0.9847
Rat acute toxicity	2.9626 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9507
hERG inhibition (predictor II)	Non-inhibitor	0.924

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
GC-MS Spectrum - EI-B	GC-MS	splash10-0006-9601000000-0e93b2309b6f4ff21792
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0002-3920000000-8a5be556648d9ff3213b

Taxonomy

Description: This compound belongs to the class of organic compounds known as 1-hydroxy-2-unsubstituted benzenoids. These are phenols that a unsubstituted at the 2-position.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Phenols
Sub Class: 1-hydroxy-2-unsubstituted benzenoids
Direct Parent: 1-hydroxy-2-unsubstituted benzenoids
Alternative Parents: Pyrazolidinones / Benzene and substituted derivatives / 1,3-dicarbonyl compounds / Carboxylic acid hydrazides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents: 1-hydroxy-2-unsubstituted benzenoid / Monocyclic benzene moiety / Pyrazolidinone / 1,3-dicarbonyl compound / Pyrazolidine / Carboxylic acid hydrazide / Azacycle / Organoheterocyclic compound / Carboxylic acid derivative / Organic oxide
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: phenols, pyrazolidines (CHEBI:76258)

Targets

Details1. Group IIE secretory phospholipase A2

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Phospholipase a2 activity
Specific Function: PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name: PLA2G2E
Uniprot ID: Q9NZK7
Uniprot Name: Group IIE secretory phospholipase A2
Molecular Weight: 15988.525 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]

Transporters

Details1. Solute carrier family 22 member 6

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name: SLC22A6
Uniprot ID: Q4U2R8
Uniprot Name: Solute carrier family 22 member 6
Molecular Weight: 61815.78 Da

References

Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:52

Oxyphenbutazone

Identification

Structure for DB03585 (Oxyphenbutazone)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Carriers

References

Transporters

References